Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL3 | P20749 | 6/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29943811 | 0.87 | BCL3 (0.65) | BCL3NPC1RAB9A | |
| SCHEMBL8161181 | 0.87 | BCL3 (0.84) | BCL3MEN1KMT2AEPHX2 | |
| SCHEMBL11484492 | 0.84 | MEN1 (0.57) | MEN1KMT2ARAB9A | |
| SCHEMBL2964718 | 0.82 | IKBKB (0.57) | MEN1KMT2A | |
| SCHEMBL27985765 | 0.82 | ALDH1A1 (0.62) | MEN1KMT2A | |
| SCHEMBL24333908 | 0.82 | NPSR1 (0.56) | MEN1KMT2A | |
| SCHEMBL13164061 | 0.82 | NPSR1 (0.59) | MEN1KMT2ANPC1RAB9A | |
| SCHEMBL11277010 | 0.81 | KDM4E (0.61) | MEN1KMT2A | |
| SCHEMBL21347710 | 0.81 | POLB (0.55) | MEN1KMT2A | |
| SCHEMBL13164063 | 0.81 | NPSR1 (0.58) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569282-B2 | Carboxamide compounds and their use | CYTOPATHFINDER, INC. (JP) | 2013-10-29 | — | — | US | disclosed |
| US-8569282-B2 | Carboxamide compounds and their use | CYTOPATHFINDER, INC. (JP) | 2013-10-29 | — | — | US | disclosed |
| WO-2011145035-A1 | NOVEL 3,5-DISUBSTITUED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES | INDIAN INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2011-11-24 | — | — | WO | disclosed |
| US-20100324035-A1 | Carboxamide Compounds and Their Use | CYTOPATHFINDER, INC. (JP) | 2010-12-23 | — | — | US | disclosed |
| US-20100324035-A1 | Carboxamide Compounds and Their Use | CYTOPATHFINDER, INC. (JP) | 2010-12-23 | — | — | US | disclosed |
| US-20100286136-A1 | DIHYDRONAPHTHYRIDINYL AND RELATED COMPOUNDS FOR USE IN TREATING OPHTHALMOLOGICAL DISORDERS | JONES SIMON | 2010-11-11 | — | — | US | disclosed |
| US-20100286136-A1 | DIHYDRONAPHTHYRIDINYL AND RELATED COMPOUNDS FOR USE IN TREATING OPHTHALMOLOGICAL DISORDERS | JONES SIMON | 2010-11-11 | — | — | US | disclosed |
| US-20100210633-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE | EPIX DELAWARE, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100210633-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE | EPIX DELAWARE, INC. (US) | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286136-A1 | DIHYDRONAPHTHYRIDINYL AND RELATED COMPOUNDS FOR USE IN TREATING OPHTHALMOLOGICAL DISORDERS | ALDH1A2, QDPR, PDE6C | BCL3 2491/4885MEN1 2469/4885KMT2A 3436/4885 |
| US-20100210633-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE | CCR2, CCR1, CCR5 | BCL3 1253/4885MEN1 4753/4885KMT2A 2026/4885 |
| US-20100324035-A1 | Carboxamide Compounds and Their Use | CCR2, CCR1, CCR5 | BCL3 1385/4885MEN1 4772/4885KMT2A 2106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.